Markets in the US down over night and the biotechnology sector...

Markets in the US down over night and the biotechnology sector continued to slide. Contributing to this was the news a late-stage test of Amgen's skin cancer drug disappointed researchers, and Halozyme suspending a study of its pancreatic cancer drug due to patient safety concerns.

I suspect similar events in Australian biotech with both Prima and Prana having disappointing trial results are weighing down the sector as a whole.

We need some good news to buoy the sector. I am hopeful Alchemia will provide that news when it's it's phase III results are released!